Ackman seeks court ruling on Allergan special meeting

William Ackman's Pershing Square Capital Management said it had filed a lawsuit seeking confirmation that a requested special shareholder meeting of Allergan Inc's shareholders would not trigger Allergan's poison pill takeover defence.

_0">

The Botox maker has rejected a $53 billion joint offer from Ackman and Canadian drugmaker Valeant Pharmaceuticals International .

Allergan said in April that its board had adopted a one-year shareholder rights plan to give it more time to consider takeover proposals.

Allergan's shareholder rights plan will trigger if a person or group acquires 10 percent or more of its shares.

The lawsuit filed in Delaware Court of Chancery followed a request to Allergan from Pershing Square on June 6 seeking confirmation that Allergan would not use its poison pill to impede Ackman's request for a special meeting.

A response from Allergan's counsel on Thursday did not provide that confirmation, Pershing Square said.

Allergan rejected a sweetened offer from Valeant and the activist investor on Tuesday. (Reporting by Natalie Grover and Sweta Singh; Editing by Ted Kerr)

Popular posts from this blog

Study Abroad USA, College of Charleston, Popular Courses, Alumni

Edinburgh Napier University Admission Process

Precious moments together...